Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function

NCT03718533 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
10
Enrollment
INDUSTRY
Sponsor class

Stopped In the context of COVID-19 pandemic, the benefit / risk ratio of the participation of a patient with pancytopenia could be compromised. The decision of this premature termination was not the consequence of any safety reason inherent to the drug.

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals